My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

Trial Profile

My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Cobimetinib (Primary) ; Erlotinib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary)
  • Indications Solid tumours; Tumours
  • Focus Therapeutic Use
  • Acronyms Mypathway
  • Sponsors Genentech
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Interim results for patients with advanced salivary cancer (n=8; data cut off: 30 Nov, 2016), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2017 Results (n=61 data cut off: Nov 30, 2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top